ITEMS IN AFP WITH KEYWORD:
Aug 1, 2007 Issue
Interventions to Improve Blood Pressure Control in Patients with Hypertension [Cochrane for Clinicians]
One large study of adults with hypertension showed that a rigorous, systematic program including regular patient review and aggressive antihypertensive drug therapy improved systolic and diastolic blood pressure and reduced all-cause mortality (7.8 to 6.4 percent at five years; number needed to trea...
Home monitoring of blood glucose and blood pressure levels can provide patients and physicians with valuable information in the management of diabetes mellitus and hypertension. Home monitoring allows patients to play an active role in their care and may improve treatment adherence and clinical outc...
Jul 1, 2006 Issue
Antihypertensive Agents for Prevention of Diabetic Nephropathy [Cochrane for Clinicians]
Angiotensin-converting enzyme (ACE) inhibitors are the only antihypertensive agents with proven effectiveness for the primary prevention of diabetic nephropathy (defined as an albumin excretion of less than 30 mg per day on three serial measurements) caused by type 1 or type 2 diabetes. However, ACE...
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends lifestyle modification for all patients with hypertension or prehypertension. Modifications include reducing dietary sodium to less than 2.4 g per day; increasing ...
The development of a national database on normative blood pressure levels throughout childhood has contributed to the recognition of elevated blood pressure in children and adolescents. The epidemic of childhood obesity, the risk of developing left ventricular hypertrophy, and evidence of the early ...
Oct 1, 2005 Issue
New AHA Recommendations for Blood Pressure Measurement [Practice Guidelines]
The American Heart Association (AHA) has published a new set of recommendations for the measurement of blood pressure to increase accuracy of clinic readings, and in recognition of major changes over the past 10 years (including the prohibition of mercury in many countries).
Olmesartan is a safe and effective antihypertensive agent. There is no evidence that olmesartan is more effective than other ARBs or ACE inhibitors. The longest peer-reviewed studies of olmesartan are of two months’ duration; thus, there is no evidence showing olmesartan’s long-term benefit for cardiovascular or all-cause mortality.
The most effective strategy to improve patient compliance with antihypertensive medication is to simplify the dosing regimen. There is more limited evidence to support a variety of motivational strategies. Patient education alone is ineffective.
May 15, 2005 Issue
Improving the Quality of Care for Patients with Hypertension [Practice Guidelines]
The National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents has issued its Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.